Psyence Group Inc. (TSE:PSYG) has released an update.
Psyence Group Inc. is advancing in the mental health sector by having its associate, Psyence Biomed, partner with Fluence and iNGENū CRO to facilitate training for a Phase IIb clinical trial involving psilocybin, a natural psychedelic compound. The collaboration aims to integrate psychedelic-assisted therapy for palliative medicine, with a trial set to begin in the second quarter of 2024, testing psilocybin in conjunction with psychotherapy on 84 patients. Psyence Group, known for its federally licensed commercial psilocybin production facility, holds a significant minority interest in Psyence Biomed.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.
